LMR Partners’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.4M Buy
1,443,800
+623,400
+76% +$9.32M 0.07% 217
2026
Q2
$12M Buy
820,400
+220,000
+37% +$3.9M 0.04% 369
2026
Q1
$11.4M Buy
600,400
+176,000
+41% +$2.85M 0.03% 374
2025
Q4
$7.42M Buy
424,400
+15,300
+4% +$288K 0.01% 478
2025
Q3
$8.45M Buy
409,100
+225,300
+123% +$5.46M 0.04% 376
2025
Q2
$3.91M Buy
183,800
+47,000
+34% +$1.07M 0.03% 514
2025
Q1
$2.64M Buy
136,800
+15,000
+12% +$301K 0.02% 596
2024
Q4
$2.17M Buy
121,800
+21,800
+22% +$423K 0.02% 578
2024
Q3
$2.19M Buy
100,000
+50,000
+100% +$699K 0.02% 582
2024
Q2
$390K Buy
+50,000
New +$270K ﹤0.01% 800

Other funds holding SMMT

LMR Partners's SMMT Position: Q3 2026 in Review

LMR Partners sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 96,177 shares — an estimated $1.44M sold.

LMR Partners first reported a position in SMMT in Q1 2021 and held it in 5 quarters. The position peaked at $1.4M in Q2 2026. 296 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • LMR Partners reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
  • LMR Partners sold 96,177 Summit Therapeutics shares in Q3 2026, an estimated $1.44M.
  • LMR Partners first reported a position in Summit Therapeutics in Q1 2021 and held it in 5 quarters.
  • LMR Partners's Summit Therapeutics position peaked at $1.4M in Q2 2026.
  • 296 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on LMR Partners's 13F filing for Q3 2026, filed 16 Nov 2026.